December 19, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Mitsui to Participate in KIFMEC Specific Purpose Company
 

Tokyo, Aug 18, 2014 (JCN) - Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). It is planned to start leasing its building to KIFMEC from September 2014.

Hyogo prefecture has been nominated as National Strategic Special Zone with an aim to promote advanced medical technology and services through the integration and collaboration among healthcare providers, R&D institutions, and manufactures.

KIFMEC will start its operation in November 2014, as a hospital that provides highly advanced medical treatment and service in liver disease and gastroenterology treatments in Kobe's Port Island which under government, industry and academic collaborations, aims to accumulate advanced medical Technology and services.

KIFMEC has appointed Dr. Koichi Tanaka, Professor Emeritus at Kyoto University as its chairman, with an aspiration to play a pivotal role in Kobe's Bio-medical innovation cluster as the international base of advanced medical technology such as living donor liver transplant surgery, and endoscopic and laparoscopic treatments.

Dr. Tanaka is active globally and is also our partner in Sing-Kobe Liver Transplant Centre Pte. Ltd. (Mitsui 49%, "SKLTC"), a clinic specializing in the treatment of liver disease and living donor liver transplant surgery, which opened in Singapore in September, 2013.

Mitsui as the shareholder of "KIFMEC specific purpose company" will support the operation of KIFMEC and its global expansion. Mitsui will align with SKLTC and utilize IHH Healthcare Bhd's network, the largest healthcare network in Asia which Mitsui invested in 2011, to introduce Japan's highly advanced medical treatment and services to the Asian region in order to contribute to the globalization of Japan's healthcare industry and to the advancement of medical treatment in Asia.


By Jun Ota Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Mitsui  News  
  Mitsui to Participate in U.S. Media Business Incubator FactoryMade Venture  (Nov 20, 2014)
  Mitsui Acquires Additional Interest in Power Generation Project in New York City  (Oct 15, 2014)
  Mitsui to Participate in KIFMEC Specific Purpose Company  (Aug 18, 2014)
  Mitsui Forms Joint Venture with a Brazil-based Major Agricultural Producer for Large Scale Farm Operation  (Sept 4, 2013)
  Basic Agreement concerning Integrated Block Development Project, and Rebuilding of Mitsui & Co. Head Office  (Aug 8, 2013)
  Mitsui & Co to Participate in Power Generation Project in South Africa  (June 6, 2013)
  Mitsui and EDF EN Mexico to Partner in Wind Power Generation Project in Mexico  (Jan 9, 2013)
  Mitsui Acquires U.S. Brand Paul Stuart  (Jan 8, 2013)
  Mitsui Takes Stake in Gestamp Automocion, Global Auto Components Supplier  (Jan 7, 2013)
  FEED Contracts Awarded for LNG Development Project in Mozambique  (Dec 21, 2012)



 Recent  Drugs & OTC News   
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)

More Drugs & OTC news...

 Recent  Medical News   
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)